Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-5163 (etelcalcetide) vs placebo in secondary hyperparathyroidism on hemodialysis
jRCT2080222613Phase 3Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Sep 2014
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD) comparing ONO-5163 (etelcalcetide) with Placebo (2 arms). Primary endpoint: Proportion of patients achieving target serum iPTH 60–240 pg/mL on Day 85. Started Sep 2014; status: completed.
02
Drugs
etelcalcetide
03
Conditions
secondary hyperparathyroidism (SHPT)chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT2080222613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222613.